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Purpose: In a multicenter randomized phase II trial of gemcitabine 
(arm A), erlotinib (arm B), and gemcitabine and erlotinib (arm C), 
similar progression-free survival (PFS) and overall survival (OS) were 
observed in all arms. We performed an exploratory, blinded, retrospec-
tive analysis of plasma or serum samples collected as part of the trial to 
investigate the ability of VeriStrat (VS) to predict treatment outcomes.
Methods: Ninety-eight patients were assessable, and the major-
ity had stage IV disease (81%), adenocarcinoma histology (63%), 
reported current or previous tobacco use (84%), and 26% had a per-
formance status (PS) of 2.
Results: In arm A, patients with VS Good (n = 20) compared with 
VS Poor status (n = 8) had similar PFS (hazard ratio [HR]: 1.21; 
p = 0.67) and OS (HR: 0.82; p = 0.64). In arm B, patients with VS 
Good (n = 26) compared with VS Poor (n = 12) had a statistically 
significantly superior PFS (HR: 0.33; p = 0.002) and OS (HR: 0.40; 
p = 0.014). In arm C, patients with VS Good (n = 17) compared 
with Poor (n = 1 5) had a superior PFS (HR: 0.42; p = 0.027) and a 
trend toward superior OS (HR: 0.48; p = 0.051). In the multivariate 
analysis for PFS, VS status was statistically significant (p = 0.011); 
for OS, VS status (p = 0.017) and PS (p = 0.005) were statistically 
significant. A statistically significant VS and treatment interaction 
(gemcitabine versus erlotinib) was observed for PFS and OS.
Conclusions: Gemcitabine is the superior treatment for elderly 
patients with VS Poor status. First-line erlotinib for elderly patients 
with VS Good status may warrant further investigation.
Key Words: Proteomics, Biomarkers, Epidermal growth factor 
receptor tyrosine kinase inhibitors, Elderly.
(J Thorac Oncol. 2013;8: 443-451)
The management of elderly patients with stage IIIB or IV non–small-cell lung cancer (NSCLC) remains controver-
sial. Cytotoxic chemotherapy remains the standard therapy 
for the majority of patients, but the optimal treatment for 
this heterogeneous patient population is unclear. Many “fit” 
elderly patients tolerate platinum-based therapy and are fre-
quently enrolled in trials of platinum-based therapy. Other 
elderly patients have cardiopulmonary comorbidities related 
to tobacco use and comorbidities associated advanced age. 
These patients represent the “frail” elderly and have difficulty 
tolerating cytotoxic chemotherapy.1 Trials investigating novel 
agents, optimal chemotherapy schedules and combinations, 
and developing biomarkers of efficacy and/or tolerance of 
therapy for the frail elderly patient population are a priority 
for the thoracic oncology community.
Beginning in 2005, we performed a noncomparative 
randomized phase II trial of gemcitabine, erlotinib, and 
erlotinib and gemcitabine in elderly patients (age 70 years or 
older) with stage IIIB or IV NSCLC.2 At the time the study 
was designed, single-agent chemotherapy was a standard of 
care based on prospective phase III trials in elderly patients.3–5 
Erlotinib, an epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitor (TKI), was a standard therapy in 
the second- and third-line settings, and a single arm phase 
II trial had revealed promising activity in elderly patients.6,7 
A phase III trial of gemcitabine and erlotinib compared with 
gemcitabine in advanced pancreatic cancer had revealed 
superior overall survival (OS) with the combination therapy.8 
The results of the intent-to-treat patient population have 
previously been published;2 neither of the investigational arms 
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(erlotinib alone or with gemcitabine) demonstrated sufficient 
activity to warrant further investigation. The role of EGFR 
mutation status in the selection of patients for first-line EGFR 
TKI therapy was not established at the time the trial was 
designed.9–12
VeriStrat is a commercially available serum or plasma 
test using matrix-assisted laser desorption ionization mass 
spectrometry methods. It was developed on a training set of 
pretreatment serum samples from patients with advanced 
NSCLC who experienced either long-term stable disease or 
early progression on gefitinib therapy.13 Mass spectra (MS) 
from these patients’ serum samples were used to define eight 
MS features (i.e., peaks), differentiating these two outcome 
groups. An algorithm utilizing these features and based on 
k-nearest neighbors classification scheme was created, and 
its parameters were optimized using additional spectra from 
the training cohort. The current commercial test uses the 
same fixed set of parameters established during the devel-
opment phase. VeriStrat assigns each sample a classification 
of VeriStrat Good or VeriStrat Poor; when an unequivocal 
 classification cannot be determined (<3% of samples), an 
indeterminate result is reported.
Validation studies of VeriStrat were performed in a 
blinded fashion using multiple single-arm cohorts of patients 
with NSCLC undergoing EGFR TKI therapy.13 Retrospective 
analysis of available plasma samples from the phase III regis-
trational trial of erlotinib, National Cancer Institute of Canada 
Clinical Trials Group BR.21, confirmed VeriStrat’s ability to 
separate patients with advanced NSCLC into groups with bet-
ter and worse outcomes with erlotinib therapy. VeriStrat sta-
tus demonstrated prognostic properties and was predictive of 
response to erlotinib. This study confirmed previous results 
that VeriStrat classification is not significantly correlated with 
EGFR or KRAS mutation status, and the absence of a corre-
lation with EGFR gene copy number.14–16 Although VeriStrat 
classification significantly correlated with certain prognostic 
characteristics, such as performance status (PS), it maintained 
a significant correlation with outcomes independent of these 
potential confounding factors in multivariate analysis.13,14
In this study we performed a retrospective analysis of 
the clinical outcomes of patients classified as VeriStrat Good 
and Veristrat Poor in each treatment arm. Although the analy-
sis in the erlotinib arm is similar to previous studies, those in 
the other treatment arms represent the first studies of VeriStrat 
testing in gemcitabine and gemcitabine plus erlotinib treated 
patients and therefore are exploratory.
PATIENTS AND METHODS
Eligibility Criteria
Patients were required to have histologic or cytologic 
diagnosis of NSCLC, AJCC 6th edition stage IIIB or IV dis-
ease, age 70 years or older, Eastern Cooperative Oncology 
Group PS of 0 to 2, and adequate bone marrow, renal, and 
hepatic function. Patients were required to have measureable 
disease according to Response Evaluation Criteria in Solid 
Tumors (RECIST).17 Patients who were unable to provide 
informed consent or participate in the Health Related Quality 
of Life (HRQOL) questionnaires were not eligible. There were 
no eligibility requirements related to histology, history of 
tobacco use, or EGFR mutation status. This trial was reviewed 
by the institutional review board of all the participating cen-
ters, and patients were required to provide informed consent 
before any study related tests were performed. The study was 
registered with Clinicaltrials.gov (NCT00283244). The pro-
tocol was amended in December 2007, and a correlative sci-
ence study with collection of peripheral blood samples was 
incorporated into the study. Participation was voluntary and 
patients who agreed to participate in the correlative science 
study signed a separate institutional review board approved 
informed consent document. Collection of tumor samples was 
not required; therefore, tumor samples are not available for 
analysis for EGFR and KRAS mutational status.
Treatment
Patients were randomly assigned to treatment arms A, 
B, or C; patients were stratified based on gender, smoking his-
tory (never or light smoking history versus current or former 
tobacco use), and PS (2 versus 0 or 1). Patients assigned to arm 
A received gemcitabine 1200 mg/m2 intravenously on days 1 
and 8 every 21 days until disease progression, unacceptable 
toxicity, or a maximum of four cycles. At the time of disease 
progression patients were offered erlotinib 150 mg daily until 
disease progression or unacceptable toxicity as part of the trial. 
Patients assigned to arm B received erlotinib 150 mg daily until 
disease progression or unacceptable toxicity. Patients assigned 
to arm C received gemcitabine 1000 mg/m2 intravenously on 
days 1 and 8 every 21 days and erlotinib 100 mg daily; patients 
received gemcitabine until disease progression, unacceptable 
toxicity, or a maximum of four cycles. After four cycles (in 
the absence of disease progression or unacceptable toxicity), 
patients continued erlotinib until disease progression or unac-
ceptable toxicity. Details about the dose adjustments for gem-
citabine and erlotinib are available in the previous publication.2
Study Assessments
Patients were required to have a staging computed 
tomography scan of the chest and abdomen (including the liver 
and adrenals) within 4 weeks of trial enrollment. Bone scan, 
positron emission tomography, and computed tomography 
scan or magnetic imaging of the brain were not required 
and were performed if clinically indicated. Disease status 
according to RECIST was assessed after cycles 2 and 4 and 
at 6 months from the beginning of therapy, and then every 2 
months or if clinically indicated. Disease status was assessed 
by the investigator. Patients underwent laboratory and physical 
examinations and toxicity assessment with each cycle.2 
Patients were evaluated using the Functional Assessment of 
Cancer Therapy for Lung Cancer (FACT-L) which consists 
of the FACT-General and the lung cancer–specific subscale 
(LCS).18,19 The FACT-L was administered at the screening visit 
(within 2 weeks of the day 1 of the first treatment cycle) or 
day 1 of the first treatment cycle (baseline), after each cycle 
(21 days), after the completion of treatment or at the time the 
patient was withdrawn from the study. The Trial Outcome 
Index-Lung (TOI-L) was the primary HRQOL analyzed.
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VeriStrat Analysis
Mass spectrometry was performed in a fully blinded 
manner on 110 available pretreatment plasma and serum 
samples sent to Biodesix (Boulder, CO). Sample aliquots 
were diluted 1:10 in HPLC-grade water and mixed (1:1 v/v) 
with matrix solution (25 mg/ml sinapinic acid dissolved 
in 50/50/0.1% acetonitrile:water:trifluoroacetic acid). The 
dilute sample-matrix mixture was spotted in triplicate on a 
matrix-assisted laser desorption ionization target in randomly 
assigned plate positions. Spectra were acquired on a Bruker 
Flextreme mass spectrometer. Each replicate spectrum con-
sisted of an average of 2000 individual spectra collected from 
various locations within the spot. The MS were then processed 
by the VeriStrat classification algorithm, which is identical to 
the one previously described by Taguchi et al.13 The VeriStrat 
test performed was the same as that provided commercially, 
and testing is conducted by Biodesix, Inc. in their Clinical 
Laboratory Improvement Amendments (CLIA)-certified 
laboratory. No adjustments were made to the test, which has 
remained fully locked since development in 2005. Testing was 
carried out blinded to all clinical information.
Statistical Methods and Study Design
This retrospective analysis was designed as an explor-
atory study of the use of the VeriStrat proteomic test in first-
line elderly patients with advanced NSCLC treated with 
gemcitabine, erlotinib, or the combination of gemcitabine 
and erlotinib. Statistical analyses were performed using 
SAS 9.2 (Cary, NC) and PRISM (GraphPad, La Jolla, CA). 
Progression-free survival (PFS) and OS were summarized 
using the Kaplan–Meier method and compared between 
treatment arms and VeriStrat groups using the log-rank test. 
Hazard ratios (HRs) between groups for time-to-event vari-
ables were calculated using Cox proportional hazard methods. 
The impact of baseline prognostic factors on outcome was 
explored with Cox regression models using forward selection, 
backward elimination, or stepwise selection of covariates with 
a fixed selection parameter of α = 0.1. Correlations of cat-
egorical variables with VeriStrat classification were assessed 
using Fisher’s exact test or a χ2 test. Statistical significance 
was set at a level of 0.05 for all analyses.
RESULTS
Between March 2006 and May 2010, 146 eligible 
patients were enrolled and initiated trial therapy. Plasma or 
serum samples were available from 110 patients, and 98 were 
assessable for analysis (Fig. 1). The clinical characteristics of 
the patients are presented in Table 1.2 Of the 98 patients in the 
VeriStrat analysis cohort, 63 were classified as VeriStrat Good 
and 35 as Poor. Tumor samples were not available for EGFR 
and KRAS mutational status making an analysis of Veristrat 
Status and tumor mutational status impossible. Of the 28 
patients in the gemcitabine arm, 12 patients received second-
line erlotinib as part of the protocol therapy. In the erlotinib 
and gemcitabine and erlotinib combination arms, 14 and 13 
patients received second-line therapy off of the protocol. An 
analysis of PFS and OS within the treatment arms was per-
formed (Fig. 2 and Table 2). In the gemcitabine arm, patients 
classified as Good (n = 20) compared with Poor (n = 8) expe-
rienced similar PFS and OS. In contrast, in the erlotinib arm, 
patients classified as Good (n = 26) compared with Poor (n = 
12) experienced significantly longer PFS (HR: 0.33; 95% CI: 
0.16–0.70; log-rank p = 0.002; median PFS of 89 and 22 days, 
respectively) and OS (HR: 0.40; 95% CI: 0.19–0.85; log-rank 
p = 0.014; median OS of 255 and 51 days, respectively). In 
the gemcitabine and erlotinib arm, patients classified as Good 
(n = 17) compared with Poor (n = 15) experienced a statisti-
cally significantly longer PFS (HR: 0.42; 95% CI: 0.19–0.93; 
log-rank p = 0.027) and a trend toward an improvement in OS 
(HR: 0.48; 95% CI: 0.23–1.02; log-rank p = 0.051).
When outcomes between treatment the erlotinib alone 
and gemcitabine alone arms were compared, the HR for PFS 
between for the VeriStrat Good and Poor groups were 0.60 
(95% CI: 0.31–1.15; log-rank p = 0.12) and 2.13 (95% CI: 
0.83–5.52; log-rank p = 0.11), respectively (HR < 1 favors 
erlotinib). The corresponding results for OS for the VeriStrat 
Good and Poor groups between erlotinib and gemcitabine 
arms were HR = 0.66 (95% CI: 0.35–1.24; log-rank p = 0.19) 
and HR = 1.62 (95% CI: 0.64–4.07; log-rank p = 0.30), respec-
tively. It should, however, be noted that in the gemcitabine 
monotherapy arm, nine of the patients classified as Good and 
three classified as Poor went on to receive erlotinib therapy 
as a second-line therapy. Outcomes on the erlotinib and gem-
citabine combination arm lay numerically in between those of 
the two monotherapy arms for both the VeriStrat groups.
In the gemcitabine alone among patients with VeriStrat 
Good and Poor, the overall response rate (ORR) was 6% and 
0%, respectively, and the disease control rate (DCR), defined as 
ORR and stable disease rate, was 60% and 62%, respectively. 
In the erlotinib arm, the ORR among patients with Veristrat 
Good and Poor was 5% and 0%, respectively, and the DCR was 
62% and 25%, respectively. In the combination arm, the ORR 
among patients with VeriStrat Good and Poor was 15% and 
10%, respectively, and the DCR was 65% and 47%, respec-
tively. No evidence of association between VeriStrat classifica-
tion and ORR or DCR was found in any of the treatment arms.
Analysis of the association of patient characteristics 
with VeriStrat classification revealed a statistically significant 
correlation between VeriStrat Good status and a PS of 0 or 
1 as well as adenocarcinoma histology compared with other 
histologies (Table 3). To adjust for these and other possible 
confounding factors, multivariate analysis was performed 
for PFS and OS (Table 4). In the multivariate analysis for 
PFS, VeriStrat status (Good versus Poor) was associated with 
longer PFS (HR: 0.51; 95% CI: 0.30–0.86; p = 0.011). There 
was a statistical trend for shorter PFS associated with PS of 
2 compared with PS 0 or 1 (HR: 1.69; 95% CI: 0.98–2.92; 
p = 0.058). In the multivariate analysis for OS, VeriStrat status 
(Good versus Poor) was associated with longer OS (HR: 0.53; 
95% CI: 0.32–0.90; p = 0.017), and PS of 2 compared with 0 
or 1 was associated with shorter OS (HR: 2.20; 95% CI: 1.27–
3.83; p = 0.005). There was a borderline significant difference 
between stage IIIB and IV, with worse survival for patients 
with stage IV compared with stage IIIB disease (HR: 1.76; 
95% CI: 0.93–3.32; p = 0.080).
When the clinical data from the gemcitabine and erlo-
tinib arms were analyzed using adjusted multivariate analysis 
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with covariate selection, the interaction between treatment 
and VeriStrat classification was shown to be significant (p < 
0.001), together with the treatment arm (p = 0.028) and sex 
(p = 0.029) for PFS (Table 5). Similar analysis for OS showed 
that the interaction was again significant (p = 0.017), this time 
together with PS (p = 0.010) and disease stage (p = 0.047) 
(Table 5). The significance of the interaction between erlotinib 
or gemcitabine treatment and VeriStrat classification indi-
cates that there is a differential benefit from these therapies 
between patients with Good and Poor VeriStrat classification, 
that is, the VeriStrat Good group benefits more from erlotinib, 
whereas Veristrat Poor group benefits more from gemcitabine.
We performed an exploratory analysis investigating if 
VeriStrat Good status and the longer PFS were associated with 
an improvement in HRQOL or lung cancer symptoms. In the 
gemcitabine alone arm, the PFS was similar in patients with 
VeriStrat Good and Poor status, and we performed an explor-
atory analysis to see if there was a difference in HRQOL or 
lung cancer symptoms related to VeriStrat status without the 
potential confounding factor of difference in PFS. These anal-
yses are retrospective and exploratory and were not designed 
to test a specific hypothesis. There did not appear to be any 
significant differences in best response to treatment analysis 
as assessed by the FACT-L, TOI-L, or the LCS (Table 6). In 
the gemcitabine arm (n = 28) and erlotinib arm (n = 36), sta-
tistically significant differences were not observed between 
Veristrat Good and Poor groups and also differences were not 
observed on the TOI-L, FACT-L, and LCS at any of the four 
individual time points or in the longitudinal HRQOL trend 
analysis (Fig. 3).
DISCUSSION
The development of predictive biomarkers for currently 
available therapies is an area of intense investigation in thoracic 
oncology. EGFR mutations and anaplastic lymphoma kinase 
rearrangements are predictive of clinical benefit of EGFR TKI 
therapy and crizotinib, respectively. It is, however, estimated 
that only approximately 20% of patients with adenocarcinoma 
will have these molecular characteristics.20 Patients with 
EGFR mutant tumors derive tremendous benefit from EGFR 
TKI therapy, but there is a significant clinical need to further 
define who benefits from EGFR TKI therapy in patients with 
EGFR wild-type tumors. VeriStrat is a commercially available 
test in the United States; it has previously been demonstrated to 
be associated with longer PFS and OS in patients treated with 
EGFR TKIs and to be predictive of response to erlotinib. Our 
retrospective analysis confirmed that patients with a VeriStrat 
Good compared with Poor status have statistically significant 
longer PFS and OS when treated with erlotinib. The median 
PFS and OS observed among elderly patients with VeriStrat 
Good status suggests benefit for first-line EGFR TKI therapy 
in this patient population. This, however, is a retrospective 
analysis, and the number of patients in this cohort is small 
(n = 26). VeriStrat Good status was associated with good PS 
146 paents eligible & 
received protocol therapy 
124 samples available
14 unevaluable
13 samples hemolyzed
1 could not generate mass 
spectra
Arm A: Gemcitabine
Good (N = 20)
Poor (N = 8)
5 samples could not be 
matched with clinical data
Samples matched with clinical data
63 samples “Good”
35 samples “Poor”
110 successful VeriStrat classificaon
64 “Good”
39 “Poor”
7 samples “indeterminate"
Arm B: Erlonib
Good (N = 26)
Poor (N = 12)
Arm C: Gemcitabine + Erlonib
Good (N = 17)
Poor (N = 15)
FIGURE 1.  Consort diagram for the study.
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and adenocarcinoma histology, which are also good prognostic 
factors. Unfortunately, we do not have additional clinical data 
to determine if there is an association with VeriStrat status with 
other clinical factors such as weight loss, site or number of 
metastases, and comorbidities. The association with VeriStrat 
Good status and good PS has been observed in other studies 
and warrants further investigation.13,21
Of concern, the patients in the erlotinib arm with Veristrat 
Poor status had poor median PFS and OS, 22 and 51 days, 
respectively. Importantly, only 14 of patients enrolled in the 
erlotinib arm received second-line therapy, and VeriStrat Poor 
status was associated with worse PS and nonadenocarcinoma 
histology.2 Patients in this cohort experienced rapid disease 
progression on first-line erlotinib and may not have received 
second-line therapy related to poor PS, comorbidities, symp-
tomatic decline, and patient and/or physician decision. The 
reasons for the poor efficacy are most likely multifactorial, but 
the data indicate erlotinib is not an acceptable first-line treat-
ment option for this patient population. Patients with Veristrat 
Poor and Good status had similar PFS and OS with single 
agent gemcitabine, and a significant interaction of treatment 
and VeriStrat status was detected. These data suggest that the 
VeriStrat test is predictive with respect to treatment, not merely 
prognostic, and that the patients with a VeriStrat Poor status 
received greater clinical benefit from single agent gemcitabine 
compared with erlotinib than those with VeriStrat Good status. 
Patients in the gemcitabine and erlotinib arm with VeriStrat 
Good compared with VeriStrat Poor  status  experienced an 
improvement in PFS and a trend toward improvement in 
OS. The lack of the association between VeriStrat status and 
improved PFS and OS in the gemcitabine alone arm in this 
analysis and the absence of an association between VeriStrat 
status and chemotherapy observed in previous trials suggests 
that the erlotinib component of the therapy is responsible for 
this observation.
This analysis is exploratory and has several deficiencies. 
The retrospective nature of this analysis and the association 
of VeriStrat Good status with certain prognostic factors could 
have created imbalances of prognostic factors in the different 
subsets; however, multivariate analyses may have adequately 
adjusted for possible confounding factors. Imbalances in the 
rate and type of poststudy therapy may have impacted the OS 
results, and type of second-line therapy was only mandated 
in the single agent gemcitabine arm. The lack of mandatory 
tumor collection as part of the eligibility criteria makes 
assessment of any correlation between VeriStrat status and 
molecular characteristics such as EGFR or KRAS mutation 
status impossible. The majority of patients enrolled had a 
history of tobacco use (approximately 85% of patients), 
40% of patients had a tumor with nonadenocarcinoma 
histology, and no responses were observed in the erlotinib 
alone arm. These data are suggestive that the rate of EGFR 
mutant NSCLC was low in this trial. There was no significant 
difference in the HRQOL outcomes in the initial trial, and 
TABLE 1.  Patient Characteristics
Characteristic Veristrat analysis Gemcitabine Erlotinib Gemcitabine/erlotinib
Number 98 28 38 32
VeriStrat status
 Good/Poor 63/35 20/8 26/12 17/15
Median age, years (range) 76 (69–90) 74 (70–86) 76 (69–86) 78 (70–90)
Stage (%)
 IIIB 19 (19) 8 (29) 3 (8) 8 (25)
 IV 79 (81) 20 (71) 35 (92) 24 (75)
Gender (%)
 Male 54 (55) 16 (57) 20 (53) 18 (56)
 Female 44 (45) 12 (43) 18 (47) 14 (44)
Performance status (%)
 0 18 (18) 7 (25) 6 (16) 5 (16)
 1 44 (45) 13 (46) 22 (58) 18 (56)
 2 25 (26) 8 (29) 9 (24) 8 (25)
 Missing 2 (2%) 0 (0) 1 (3) 1 (3)
Smoking history (%)
 Never or light 13 (13) 3 (11) 5 (13) 5 (16)
 Current or former 82 (84) 23 (82) 32 (84) 27 (84)
 Missing 3 (3) 2 (7) 1 (3) 0 (0)
Histology (%)
 Adenocarcinoma 63 (64) 17 (61) 24 (63) 22 (69)
 Squamous 14 (14) 5 (18) 5 (13) 4 (12)
 NOSa 20 (20) 5 (18) 9 (24) 6 (19)
 Large cell carcinoma 1 (1) 1 (4) 0 (0) 0 (0)
aIncludes one patient with giant cell histology.
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FIGURE 2.  Kaplan–Meier plots by 
VeriStrat status (Good and Poor) 
for (A) PFS in the erlotinib arm, (B) 
OS in the erlotinib arm, (C) PFS in 
the gemcitabine arm, (D) OS in 
the gemcitabine arm, (E) PFS in the 
erlotinib+gemcitabine arm, (F) OS 
in the erlotinib+gemcitabine arm.
TABLE 2.  Clinical Outcome of Veristrat Good compared to Poor
Treatment arm No. of patients Progression-free survival Overall survival
Gemcitabine HR: 1.21; 95% CI: 0.51–2.88; p = 0.67 HR: 0.82, 95% CI: 0.35–1.90; p = 0.64
Good: 20 Median PFS Good: 133 days Median OS Good: 201 days
Poor: 8 Median PFS Poor: 137 days Median OS Poor: 197 days
Erlotinib HR: 0.33; 95% CI: 0.16–0.70; p = 0.002 HR = 0.40; 95% CI: 0.19–0.85; p = 0.014
Good: 26 Median PFS Good: 89 days Median OS Good: 255 days
Poor: 12 Median PFS Poor: 22 days Median OS Poor: 51 days
Gemcitabine/erlotinib HR: 0.42; 95% CI: 0.19–0.93; p = 0.027 HR: 0.48; 95% CI: 0.23–1.02; p = 0.051
Good: 17 Median PFS Good: 122 days Median OS Good: 302 days
Poor: 15 Median PFS Poor: 89 days Median OS Poor: 106 days
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we wanted to test the hypothesis that the significant efficacy 
difference between the Veristrat Good and Poor subgroups in 
the erlotinib arm may have resulted in differences in HRQOL. 
The sample size for this analysis was small, and the short PFS 
observed in the VeriStrat Poor group treated with erlotinib 
limited the number of HRQOL assessments available for 
each patient. The utility of these analyses is limited and the 
purpose of including the results was to provide preliminary 
data for future studies.
This is the first report of the comparison of VeriStrat 
status in the elderly patients treated with erlotinib or with 
single-agent chemotherapy that demonstrates how a serum or 
plasma test, with no need of biopsy, may be particularly useful. 
Patients with VeriStrat Poor status should not receive erlotinib 
therapy but may be good candidates for gemcitabine treatment. 
Since this trial was developed in 2005, a phase III trial 
compared carboplatin and weekly paclitaxel to single-agent 
chemotherapy (gemcitabine or vinorelbine); a statistically 
significant improvement in PFS and OS was observed with the 
combination treatment.22 This trial established double-agent 
platinum-based therapy as a standard therapy for appropriate 
patients. Many elderly patients are, however, “frail” and may 
TABLE 3.  Patient characteristics by VeriStrat classification
VeriStrat Good VeriStrat Poor p Value
Number 63 35
Treatment arm
 Gemcitabine 20 8 0.27
 Erlotinib 26 12
 Gemcitabine/erlotinib 17 15
Gender
 Male 34 20 0.83
 Female 29 15
Ethnicity
 White 57 33 0.71
 Nonwhitea 6 2
Smoking history
 Everb 50 32 0.13
 Never 11 2
ECOG PS
 0 or 1 52 19 0.004
 2 10 15
Histology
 Adenocarcinoma 45 17 0.03
 Other histologies 18 18
Stage
 IIIB 10 9 0.29
 IV 53 26
aIncludes African American (n = 6), Asian (n = 1), unknown (n = 1).
bDefined as current or former.
TABLE 4.  Multivariate Analysis for Progression-free survival and Overall Survival
Factor Comparison PFS hazard ratio OS hazard ratio
VeriStrat status Good vs. Poor 0.51 (95% CI: 0.30–0.86), p = 0.011 0.53 (95% CI: 0.32–0.90), p = 0.017
Histology Other histologies vs. adenocarcinoma 0.95 (95% CI: 0.72–1.25), p = 0.713 0.87 (95% CI: 0.65–1.16), p = 0.335
Race Nonwhite vs. white 0.93 (95% CI: 0.39–2.24), p = 0.875 0.86 (95% CI: 0.35–2.08), p = 0.730
Gender Female vs. male 1.17 (95% CI: 0.74–1.84), p = 0.497 1.17 (95% CI: 0.73–1.88), p = 0.522
Treatment arm Erlotinib vs. gemcitabine 0.65 (95% CI: 0.36–1.18), p = 0.158 0.71 (95% CI: 0.40–1.25), p = 0.232
Treatment arm Gemcitabine/erlotinib vs. gemcitabine 0.86 (95% CI: 0.50–1.49), p = 0.593 0.76 (95% CI: 0.43–1.35), p = 0.352
Smoking history Never vs. ever 0.94 (95% CI: 0.48–1.86), p = 0.864 0.78 (95% CI: 0.38–1.59), p = 0.485
Performance status 2 vs. 0 or 1 1.69 (95% CI: 0.98–2.92), p = 0.058 2.20 (95% CI: 1.27–3.83), p = 0.005
Stage IV vs. III B 1.49 (95% CI: 0.82–2.71), p = 0.197 1.76 (95% CI: 0.93–3.32), p = 0.080
CI, confidence interval.
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not be candidates for platinum-based therapy, and the optimal 
management for this patient population remains unclear. A 
prospective phase II trial comparing erlotinib to single-agent 
chemotherapy in elderly patients as first-line therapy who 
are not candidates for double-agent platinum-based therapy 
with VeriStrat Good status may be worth pursuing to further 
investigate the use of this minimally invasive test to select 
patients for therapy. Since this trial would be exploratory, a 
potential primary end point would be PFS with the goal of 
demonstrating an improvement in PFS of 1.5 times or greater 
than the control arm before pursing larger validation trials. 
An ongoing randomized trial in the second-line setting is 
prospectively stratifying patients based on VeriStrat status and 
is comparing erlotinib to docetaxel or pemetrexed.23 Until the 
results of the prospective clinical trial are available, clinicians 
should not use VeriStrat status for selection erlotinib or 
chemotherapy in routine clinical practice.
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